Lin Jizhen | Cancer immunotherapy | Best Researcher Award

Posted on by Neuroscientists

Prof. Lin Jizhen | Cancer immunotherapy | Best Researcher Award

Prof.  Lin Jizhen, Union Hospital, Fujian Medical University, China.

Dr. Jizhen Lin is a distinguished physician-scientist whose career has been defined by an unwavering dedication to the field of auditory molecular biology. With his foundational medical education from Fujian Medical University and advanced research training in biochemistry and molecular biology at the University of Minnesota, he has seamlessly blended clinical acumen with scientific innovation. His professional roles have evolved from intern and research fellow to Associate Professor and Laboratory Director, reflecting a career rich in mentorship, discovery, and leadership. His research has focused extensively on otitis media and the molecular mechanisms of hearing, contributing valuable insights into the pathophysiology and potential treatments of auditory disorders.

Profile

Scopus

 

📚 Early Academic Pursuits

Dr. Jizhen Lin’s academic journey began with a strong foundation in medicine at Fujian Medical University, Fuzhou, China, where he earned his M.D. in 1982 and an M.S. in Otolaryngology in 1987. His thirst for advanced knowledge and scientific discovery later brought him to the University of Minnesota, Minneapolis, where he immersed himself in the fields of biochemistry and molecular biology, further enriching his expertise and setting the stage for a robust research career in auditory sciences.

🧪 Professional Endeavors

Dr. Lin’s professional path has been marked by consistent dedication and a progressive climb through academic and research positions. His early clinical exposure as an intern at Union Hospital in Fujian laid the groundwork for his subsequent transition into research. Between 1992 and 1995, he served as an International Research Fellow at the Otitis Media Research Center (OMRC), University of Minnesota. He continued to make strides as a Research Scientist and Co-director of the Otopathology-Molecular Biology Laboratory, contributing significantly to auditory molecular biology. His leadership abilities culminated in his appointment as Director of the Auditory Molecular Biology Laboratory, and he has been serving as an Associate Professor in the Department of Otolaryngology at the University of Minnesota Medical School since 2008.

🔬 Contributions and Research Focus

Throughout his career, Dr. Lin has concentrated on unraveling the complexities of auditory molecular biology with a primary focus on otitis media, a prevalent childhood disease. His contributions have been instrumental in bridging clinical otolaryngology with molecular science, employing biochemical tools to investigate the pathogenesis of auditory disorders. His laboratory has played a critical role in advancing understanding of the genetic and cellular mechanisms that underpin hearing loss and middle ear infections, particularly through innovative translational approaches.

🏅 Accolades and Recognition

Dr. Lin’s relentless pursuit of scientific excellence and impactful research has earned him widespread recognition in the field of otolaryngology. His tenure as a Graduate Faculty advisor reflects not only his dedication to mentorship but also the high regard his peers and the academic community have for his expertise. While he may not be adorned with numerous public awards, the esteem in which he is held by colleagues and students alike underscores the quiet yet profound impact of his scholarly work.

🌍 Impact and Influence

The influence of Dr. Lin’s research extends beyond the laboratory, as his findings have contributed meaningfully to clinical practices and therapeutic approaches in otolaryngology. By identifying key molecular targets and pathways involved in auditory disorders, his work continues to shape the development of novel diagnostics and treatments. Furthermore, his role in international research collaborations underscores his commitment to knowledge exchange and global scientific advancement.

🧠 Legacy and Future Contributions

Dr. Lin’s legacy is firmly rooted in the integration of molecular science with clinical otolaryngology, a field he has helped shape through decades of dedicated research and academic mentorship. As a mentor to future scientists and a contributor to critical advancements in auditory health, he remains a cornerstone in the bridge between basic science and patient care. Looking forward, his ongoing work in auditory molecular biology is poised to further uncover the mechanisms of hearing and hearing loss, promising new frontiers in medical intervention and auditory health.

🧬 Lifelong Commitment to Hearing Science

Dr. Lin’s career embodies a lifelong commitment to auditory science, from the clinic to the lab. His seamless blend of clinical knowledge, molecular expertise, and research leadership has fostered a rich legacy in otolaryngology. With ongoing contributions to scientific understanding and future discoveries on the horizon, Dr. Lin continues to inspire a generation of researchers and clinicians dedicated to improving hearing health worldwide.

Publication

  1. Title: Cell-free transcription amplification-based split-type electrochemical sensor using enzyme-linked magnetic microbeads for minimal residual leukemia detection
    Authors: Luying Yu, Jinyuan Chen, Huanjiao Weng, … Xinhua Lin, Guangxian Zhong
    Year: 2025

 

  1. Title: Antibody screening-assisted multichannel nanoplasmonic sensing chip based on SERS for viral screening and variants identification
    Authors: Yi Liu, Huanjiao Weng, Zhiwei Chen, … Shangyuan Feng, Duo Lin
    Year: 2025

 

  1. Title: tRNA methyltransferase DNMT2 promotes hepatocellular carcinoma progression and enhances Bortezomib resistance through inhibiting TNFSF10
    Authors: Junzhong Lai, Linqin Chen, Qiumei Li, … Jizhen Lin, Qi Chen
    Year: 2025

 

  1. Title: Carrimycin ameliorates lipopolysaccharide and cecal ligation and puncture-induced sepsis in mice
    Authors: Junzhong Lai, Jiadi Liang, Kunsen Chen, … Qi Chen, Jizhen Lin
    Year: 2024

 

  1. Title: B7H3 targeting gold nanocage pH-sensitive conjugates for precise and synergistic chemo-photothermal therapy against NSCLC
    Authors: Bing Chen, Kaifan Zheng, Shubin Fang, … Jizhen Lin, Xinhua Lin
    Year: 2023

 

  1. Title: A drug-delivery depot for epigenetic modulation and enhanced cancer immunotherapy
    Authors: Junzhong Lai, Jiadi Liang, Yong Zhang, … Jizhen Lin, Qi Chen
    Year: 2023

 

  1. Title: Ultrasensitive detection of SARS-CoV-2 antigen using surface-enhanced Raman spectroscopy-based lateral flow immunosensor
    Authors: Shuxia Lai, Yi Liu, Shubin Fang, … Jizhen Lin, Shangyuan Feng
    Year: 2023

 

  1. Title: Retraction Note to: Linc00210 drives Wnt/β-catenin signaling activation and liver tumor progression through CTNNBIP1-dependent manner
    Authors: Xiaomin Fu, Xiaoyan Zhu, Fujun Qin, … Qinxian Zhang, Quanli Gao
    Year: Not specified

 

  1. Title: SFPQ Promotes Lung Cancer Malignancy via Regulation of CD44 v6 Expression
    Authors: Libang Yang, Jiangbo Yang, Blake A. Jacobson, … Craig A. Henke, Jizhen Lin
    Year: 2022

 

✅ Conclusion

Dr. Lin’s lifelong commitment to understanding the science of hearing has positioned him as a pioneering figure in otolaryngology. Through decades of research, academic guidance, and clinical collaboration, he has built a legacy rooted in translational science and patient-centered innovation. His work continues to influence both basic research and clinical practice, promising a future where auditory health is better understood and more effectively managed. As a scientist, mentor, and innovator, Dr. Lin stands as an enduring contributor to the advancement of hearing science.

Soumya Basu | miRNA Biology | Excellence Award (Any Scientific field)

Posted on by Neuroscientists

Dr. Soumya Basu | miRNA Biology | Excellence Award (Any Scientific field)

Dr. Soumya Basu, Dr. D. Y. Patil Biotechnology and Bioinformatics Institute,  India.

Dr. Soumya Basu is a distinguished scientist and academic specializing in cancer and translational research. With a Ph.D. in Life Sciences and over 18 years of research experience, he has made significant contributions to understanding drug-resistant cancer and targeted therapies. His academic journey spans multiple disciplines, including microbiology, medical writing, and artificial intelligence applications in cancer research. As an Associate Professor at Dr. D. Y. Patil Biotechnology and Bioinformatics Institute, he has played a pivotal role in scientific mentorship, research advancements, and cross-disciplinary collaborations. His expertise in molecular oncology, cell-based assays, and small molecule design has led to impactful research, widely recognized in the scientific community through publications and citations.

 

Profile

Google Scholar

 

Early Academic Pursuits 🎓

From an early stage, Dr. Soumya Basu exhibited a keen interest in the sciences, embarking on an academic journey that laid the foundation for an illustrious career in life sciences and cancer research. He earned a Bachelor of Science in Physics, Chemistry, and Mathematics from the University of Burdwan, followed by a Master’s degree in Microbiology from the University of Kalyani. His unwavering passion for research led him to pursue a Ph.D. in Life Sciences at Jadavpur University, focusing on reactive oxygen species-mediated targeted therapy in drug-resistant cancer. Further enhancing his expertise, he pursued an Advanced Diploma in Medical Writing and Regulatory Affairs and later completed an Advanced Postgraduate course in Artificial Intelligence and Machine Learning from the University of Texas at Austin, reinforcing his multidisciplinary approach to modern scientific research.

Professional Endeavors 🎮

Dr. Basu’s professional journey is marked by his dedication to academia and translational research. He currently serves as an Associate Professor and Principal Investigator at the Cancer and Translational Research Centre, Dr. D. Y. Patil Biotechnology and Bioinformatics Institute, Pune. His tenure at Dr. D. Y. Patil Vidyapeeth spans over a decade, where he initially joined as an Assistant Professor before rising to his current role. Prior to this, he contributed significantly as a Research Associate at the Molecular Functional Imaging Laboratory, ACTREC, Tata Memorial Center, and held esteemed positions as a Senior Research Fellow at the Chittaranjan National Cancer Institute (CNCI) and a Project Assistant at Jadavpur University and the University of Calcutta. His early teaching career at Kulti College further highlights his commitment to education and mentorship.

Contributions and Research Focus 🧑‍�‍🔬

Dr. Basu’s research is deeply rooted in cancer therapeutics, particularly in drug-resistant malignancies. His work spans multiple domains, including animal cell culture, cell-based assays, small molecule design and validation, and non-coding RNA research. With a strong emphasis on translational research, he has been at the forefront of developing novel therapeutic strategies targeting drug-resistant cancer cells. His contributions to molecular oncology and biotechnology have paved the way for advancements in personalized medicine, integrating computational approaches like artificial intelligence and machine learning to enhance predictive models in cancer treatment.

Accolades and Recognition 🏆

Over his distinguished career, Dr. Basu has garnered widespread recognition for his contributions to scientific research. His prolific publication record, including books, book chapters, research articles, and technical reports, attests to his commitment to advancing knowledge in cancer biology. His Google Scholar profile boasts an H-index of 14, with over 550 citations, underscoring the impact of his research in the global scientific community. His expertise in scientific writing and editing has also made him a sought-after mentor and collaborator in academia.

Impact and Influence 📈

Dr. Basu’s work has had a profound impact on the field of oncology, with his research findings influencing therapeutic strategies and treatment paradigms. His mentorship and guidance have inspired numerous young researchers, fostering the next generation of scientists dedicated to battling cancer. His contributions extend beyond the laboratory, as he actively participates in knowledge dissemination through conferences, workshops, and academic collaborations. His ability to bridge the gap between fundamental research and clinical application has positioned him as a thought leader in the field.

Legacy and Future Contributions 🌟

As a scientist and educator, Dr. Basu’s legacy is defined by his relentless pursuit of innovation in cancer research. His ongoing work aims to refine targeted therapies, explore novel drug delivery systems, and harness artificial intelligence for more effective cancer diagnostics and treatment. With a vision to create a lasting impact on cancer care, he continues to drive transformative research initiatives. His unwavering commitment to scientific excellence ensures that his contributions will shape the future of oncology for years to come.

 

Publication

  1. Synthesis, spectroscopic characterization, X-ray powder structure analysis, DFT study and in vitro anticancer activity of N-(2-methoxyphenyl)-3-methoxysalicylaldimine

    • Authors: B Chattopadhyay, S Basu, P Chakraborty, SK Choudhuri, AK Mukherjee, …
    • Year: 2009

 

  1. Targeting mitochondrial cell death pathway to overcome drug resistance with a newly developed iron chelate

    • Authors: A Ganguly, S Basu, P Chakraborty, S Chatterjee, A Sarkar, M Chatterjee, …
    • Year: 2010

 

  1. Probing intermolecular interactions and binding stability of kaempferol, quercetin and resveratrol derivatives with PPAR-γ: docking, molecular dynamics and MM/GBSA approach

    • Authors: KB Lokhande, S Ballav, RS Yadav, KV Swamy, S Basu
    • Year: 2022

 

  1. Use of BRET to study protein–protein interactions in vitro and in vivo

    • Authors: S Dimri, S Basu, A De
    • Year: 2016

 

  1. Redox active copper chelate overcomes multidrug resistance in T-lymphoblastic leukemia cell by triggering apoptosis

    • Authors: A Ganguly, S Basu, K Banerjee, P Chakraborty, A Sarkar, M Chatterjee, …
    • Year: 2011

 

  1. PPAR-γ partial agonists in disease-fate decision with special reference to cancer

    • Authors: S Ballav, B Biswas, VK Sahu, A Ranjan, S Basu
    • Year: 2022

 

  1. Drug repurposing—an emerging strategy in cancer therapeutics

    • Authors: JA Khadija Shahab Turabi, Ankita Deshmukh, Sayan Paul, Dayanand Swami, S Basu
    • Year: 2022

 

  1. Exploring conformational changes of PPAR-Ɣ complexed with novel kaempferol, quercetin, and resveratrol derivatives to understand binding mode assessment: a small-molecule study

    • Authors: KB Lokhande, S Ballav, N Thosar, KV Swamy, S Basu
    • Year: 2020

 

Conclusion 🌟

Dr. Soumya Basu’s career is a testament to his unwavering dedication to cancer research and academia. His contributions to targeted therapies, translational oncology, and biomedical advancements continue to influence both scientific understanding and clinical applications. Through his mentorship and research initiatives, he is shaping the next generation of scientists while driving forward innovative solutions for cancer treatment. With his ongoing efforts in integrating AI with biomedical sciences, Dr. Basu remains at the forefront of cutting-edge cancer research, ensuring a lasting impact on the field.

 

 

 

 

Dinh Phong Son | CircRNA | Best Researcher Award

Posted on by Neuroscientists

Dr. Dinh Phong Son | CircRNA | Best Researcher Award

Dr. DINH PHONG SON, DUYTAN UNIVERSITY, Vietnam.

Dr. Dinh Phong Son is a researcher specializing in laboratory medicine techniques with a Ph.D. in Molecular Medicine from Guangxi Medical University, China. His research focuses on modern molecular biology techniques, particularly the identification of potential biomarkers for early disease diagnosis and targeted therapy. His studies explore systemic diseases such as diabetes, cardiovascular diseases, and cancer, emphasizing gene editing technologies like CRISPR/Cas9. His recent publications contribute to the understanding of regulatory RNA networks and their implications in disease mechanisms, providing a foundation for future studies on molecular interactions and targeted drug development.

Profile

Orcid

 

🎓 Early Academic Pursuits

From the very beginning of my academic journey, I was deeply fascinated by the intricate mechanisms of life at a molecular level. My pursuit of knowledge led me to study Laboratory Medicine Technique at Hue University of Medicine and Pharmacy, Vietnam, where I honed my expertise in diagnostic methodologies and medical laboratory sciences. With an insatiable thirst for discovery, I furthered my education by earning a Doctorate (Ph.D.) in Molecular Medicine from Guangxi Medical University, China. This academic foundation set the stage for my dedication to the field of molecular biology, shaping my vision to explore genetic markers and innovative diagnostic tools.

👩‍🎓 Professional Endeavors

Currently, I serve at Duy Tan University, College of Medicine and Pharmacy, where I actively contribute to research, mentoring, and academic discourse. My work primarily revolves around molecular diagnostics, genetic analysis, and disease biomarker identification, aiming to bridge the gap between molecular biology and clinical applications. With advancements in next-generation sequencing (NGS) and bioinformatics databases, I continually seek new pathways to enhance the precision of disease detection and treatment strategies.

🧪 Contributions and Research Focus

My research is deeply rooted in molecular medicine, focusing on the identification of potential biomarkers for the early diagnosis of systemic diseases such as diabetes, cardiovascular diseases, stroke, and cancer. My investigations also extend to exploring gene targets for pharmacological studies, assisting in drug development through the modulation of gene expression using cutting-edge technologies like CRISPR/Cas9, gene overexpression, and silencing approaches. Furthermore, my work delves into the complex LncRNA/CircRNA/miRNA/gene/protein-drug interaction networks, paving the way for theoretical models that could revolutionize targeted therapy research.

 

💎 Impact and Influence

The impact of my research extends beyond academia, as it plays a crucial role in early disease screening, personalized medicine, and therapeutic advancements. By leveraging molecular networks, I aim to facilitate the development of precise diagnostic tools and gene-targeted interventions, significantly improving patient outcomes. My research findings have the potential to reshape biomedical applications and create avenues for innovative treatment strategies across various diseases.

🌟 Legacy and Future Contributions

Looking ahead, my aspirations remain steadfast in expanding molecular biology research, particularly in uncovering novel biomarkers and refining gene-editing techniques. As the field continues to evolve, I hope to contribute to the refinement of therapeutic gene modifications and biomarker-based diagnostics. With sustained efforts and collaborations, I envision a future where my research serves as a cornerstone for breakthroughs in precision medicine, targeted gene therapy, and advanced molecular diagnostics.

👨‍💼 Professional Collaborations and Memberships

As an active member of the scientific community, I engage in collaborations and professional affiliations to foster knowledge exchange and multidisciplinary research. My involvement in editorial appointments, consultancy projects, and industry partnerships enables me to extend my research impact, ensuring that molecular medicine continues to advance for the benefit of humanity.

 

Publication

  • Title: Identification and assessment of hub genes and miRNAs coregulatory associated with immune infiltrations and drug interactions in latent tuberculosis based on Microarray Data analysis, molecular docking, and dynamic simulation
    Authors: PhongSon Dinh, ChauMyThanh Tran, ThiPhuongHoai Dinh, Hai-Anh Ha, Aigul Utegenova, Awais Ali, Abdulaziz Alamri
    Year: 2025

 

  • Title: Hsa_circRNA_0000284 acts as a ceRNA to participate in coronary heart disease progression by sponging miRNA-338-3p via regulating the expression of ETS1
    Authors: PhongSon Dinh, ChauMyThanh Tran, ThiPhuongHoai Dinh, Awais Ali, ShangLing Pan
    Year: 2024

 

  • Title: Potential diagnostic value of serum microRNAs for 19 cancer types: a meta-analysis of bioinformatics data
    Authors: ChauMyThanh Tran, PhongSon Dinh
    Year: 2024

 

  • Title: Identification of hsa_circ_0001445 of a novel circRNA-miRNA-mRNA regulatory network as potential biomarker for coronary heart disease
    Authors: PhongSon Dinh, JunHua Peng, ThanhLoan Tran, DongFeng Wu, ChauMyThanh Tran, ThiPhuongHoai Dinh, ShangLing Pan
    Year: 2023

 

  • Title: Construction of miRNAs and gene expression profiles associated with ischemic cardiomyopathy: Bioinformatics analysis
    Authors: PhongSon Dinh, Jun-Hua Peng, ChauMyThanh Tran, ThanhLoan Tran, Shang-Ling Pan
    Year: 2022

 

Conclusion

Dr. Son’s research plays a crucial role in advancing molecular biology by identifying key biomarkers and regulatory networks for disease screening and treatment. His work in gene-targeted therapy and RNA interaction networks lays the groundwork for future innovations in precision medicine. Despite challenges in resources and time, his commitment to molecular research aims to drive further advancements in understanding and treating complex diseases.

Bastian Höchst | Onco- Immunology | Best Researcher Award

Posted on by Neuroscientists

Dr. Bastian Höchst | Onco- Immunology | Best Researcher Award

Dr. Bastian Höchst,  Institute of Molecular Immunology, MRI, TUM, Germany.

Bastian Höchst is a distinguished molecular immunologist whose career spans groundbreaking research, impactful teaching, and valuable contributions to the scientific community. His academic journey began with a focus on biology and culminated in a doctorate on immune regulation in liver tumors. As a Research Group Leader at the Technical University of Munich, he investigates the complex interplay of immune cells and tissues in acute and chronic inflammation. His pioneering discoveries, such as the mechanisms governing myeloid suppressor cells and immune-regulatory metabolite transfer, have advanced understanding in the field.

Profile

Google Scholar

🌱 Early Academic Pursuits

Bastian Höchst began his academic journey with a passion for understanding the intricate mechanisms of biology. From 1999 to 2005, he pursued his studies in Biology at the University of Bonn and Hamburg, laying the foundation for his future endeavors in molecular immunology. His academic curiosity led him to pursue a doctorate at the Medical School Hannover under the guidance of Prof. Dr. Tim F. Greten. His doctoral research focused on identifying and characterizing myeloid-derived suppressor cells in patients with hepatocellular carcinoma, marking the beginning of his impactful contributions to the field of immunology.

🔬 Professional Endeavors

Currently serving as a Research Group Leader at the Institute of Molecular Immunology, Klinikum rechts der Isar, Technical University of Munich (TUM), Bastian Höchst has dedicated his career to unraveling the complexities of immune regulation. His journey in academia has been marked by significant roles, including his previous tenure as a Research Group Leader at the Institute for Animal Physiology and Immunology, Wissenschaftszentrum Weihenstephan, TUM. Additionally, his postdoctoral fellowship at the Institute of Molecular Medicine and Experimental Immunology at the University of Bonn further honed his expertise in immune mechanisms.

🧪 Contributions and Research Focus

Bastian Höchst’s research delves into immune regulation within acute and chronic inflammatory processes, with a particular focus on tissue-specific mechanisms. He has made groundbreaking discoveries, including elucidating the pathways that govern the generation of myeloid suppressor cells in liver tumors. Furthermore, his innovative work revealed that the intercellular transfer of immune-regulatory metabolites is critical to T-cell effector functions. His research has significantly advanced the understanding of immune responses in disease contexts, bridging gaps in immunological knowledge.

🎓 Teaching and Mentorship

A dedicated educator, Bastian Höchst has been actively involved in teaching since 2010, inspiring students in life sciences programs at TUM. His lectures on topics such as onco-immunology, immune metabolism, and immunotherapy provide invaluable insights to aspiring scientists. Through lab courses on immune cell phenotyping and advanced techniques like spectral flow cytometry, he has empowered students with the skills to explore the complexities of immunology. His teaching contributions extend beyond knowledge dissemination, fostering a generation of critical thinkers and innovators.

📜 Accolades and Recognition

Bastian’s expertise has been recognized through his habilitation and venia legendi for Molecular Immunology, under the mentorship of Prof. Dr. Percy Knolle. His contributions as a scientific reviewer for prestigious journals like Hepatology, Journal of Hepatology, and Frontiers in Immunology further reflect his authority in the field. Additionally, his role in evaluating grant applications for the Deutsche Forschungsgemeinschaft (DFG) underscores his impact on shaping future research initiatives.

🌍 Impact and Influence

Through his research, teaching, and reviews, Bastian Höchst has left an indelible mark on the field of molecular immunology. His work not only uncovers critical mechanisms of immune regulation but also provides pathways for therapeutic advancements in inflammatory and tumor-related conditions. His contributions influence both scientific understanding and practical applications, addressing global challenges in health and disease management.

🌟 Legacy and Future Contributions

Bastian Höchst’s journey is one of passion, discovery, and impact. As he continues to lead groundbreaking research, he sets the stage for a future where immune-based therapies are revolutionized. His legacy lies in his ability to connect fundamental research with real-world applications, inspiring colleagues and mentees alike. With his unwavering commitment to scientific exploration, Bastian Höchst is poised to shape the future of molecular immunology, paving the way for transformative breakthroughs.

Publication

  • A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4+ CD25+ Foxp3+ T cells
    Authors: B. Höchst, L.A. Ormandy, M. Ballmaier, F. Lehner, C. Krüger, M.P. Manns, …
    Year: 2008

 

  • Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor
    Authors: B. Höchst, T. Voigtlaender, L. Ormandy, J. Gamrekelashvili, F. Zhao, …
    Year: 2009

 

  • Functional classification of memory CD8+ T cells by CX3CR1 expression
    Authors: J.P. Böttcher, M. Beyer, F. Meissner, Z. Abdullah, J. Sander, B. Höchst, …
    Year: 2015

 

  • Plasticity of human Th17 cells and iTregs is orchestrated by different subsets of myeloid cells
    Authors: B. Höchst, J. Gamrekelashvili, M.P. Manns, T.F. Greten, F. Korangy
    Year: 2011

 

  • S100A9 a new marker for monocytic human myeloid‐derived suppressor cells
    Authors: F. Zhao, B. Höchst, A. Duffy, J. Gamrekelashvili, S. Fioravanti, M.P. Manns, …
    Year: 2012

 

  • Regulatory myeloid cells paralyze T cells through cell–cell transfer of the metabolite methylglyoxal
    Authors: T. Baumann, A. Dunkel, C. Schmid, S. Schmitt, M. Hiltensperger, K. Lohr, …
    Year: 2020

 

  • Kupffer cell-derived Tnf triggers cholangiocellular tumorigenesis through JNK due to chronic mitochondrial dysfunction and ROS
    Authors: D. Yuan, S. Huang, E. Berger, L. Liu, N. Gross, F. Heinzmann, M. Ringelhan, …
    Year: 2017

 

  • Low-dose cyclophosphamide treatment impairs regulatory T cells and unmasks AFP-specific CD4+ T-cell responses in patients with advanced HCC
    Authors: T.F. Greten, L.A. Ormandy, A. Fikuart, B. Höchst, S. Henschen, M. Hörning, …
    Year: 2010

 

Conclusion

Bastian Höchst’s career exemplifies dedication to advancing molecular immunology through innovative research, education, and mentorship. His contributions have shaped the understanding of immune responses in disease contexts, offering hope for novel therapeutic approaches. As he continues to lead impactful research and foster new talent, Bastian Höchst remains a visionary in his field, poised to drive future breakthroughs that bridge science and medicine for the benefit of society.

 

Mr. Gan Liu | Gastrointestinal cancer| Best Researcher Award

Posted on by Neuroscientists

Mr. Gan Liu | Gastrointestinal cancer| Best Researcher Award

Mr. Gan Liu, the Affiliated Hospital of Qingdao University, China.

liu gan is a dedicated researcher and educator at qingdao university, specializing in gastric cancer diagnostics and treatment. his academic journey laid the foundation for innovative contributions to medical imaging and surgical oncology. through groundbreaking work in radiomics and robotic surgery, he has advanced diagnostic precision and surgical outcomes, significantly influencing global oncology practices. his achievements have garnered widespread recognition, marking him as a leader in his field.

 

profile

Scopus

early academic pursuits

liu gan began his academic journey with a strong foundation in medical sciences, focusing on the complexities of gastric cancer. his early education laid the groundwork for a career driven by curiosity and precision. by immersing himself in medical imaging and oncology, liu honed the skills necessary for innovative research. his dedication to learning and his commitment to advancing healthcare positioned him as a rising scholar in his field.

professional endeavors

liu's career flourished at qingdao university, where he took on pivotal roles in medical research and education. as a leading figure in oncology, he collaborated with multidisciplinary teams to develop advanced diagnostic and treatment protocols for gastric cancer. his expertise in medical imaging, particularly enhanced ct and radiomics, underscored his dedication to leveraging technology for better patient outcomes.

contributions and research focus

liu gan’s research centers on improving diagnostic precision and surgical outcomes for gastric cancer patients. he played a critical role in developing a deep learning radiomics nomogram to predict the response of metastatic lymph nodes to neoadjuvant chemotherapy. his investigations into robotic and laparoscopic total gastrectomy have provided valuable insights into optimizing surgical techniques, contributing significantly to evidence-based practice in oncology.

accolades and recognition

liu’s groundbreaking work has earned him accolades in both national and international academic circles. his contributions to gastric cancer research have been celebrated through awards, publications, and invitations to prestigious conferences. his role as a thought leader in medical imaging and oncology has cemented his reputation as a pioneer in his field.

impact and influence

liu’s work has transformed the understanding and management of gastric cancer, impacting clinical practice and patient care globally. his innovative approaches to medical imaging and surgery have set new standards in oncology. by combining technology with medical expertise, liu has influenced a new generation of researchers and clinicians, inspiring advancements in cancer treatment.

legacy and future contributions

as a dedicated researcher and educator, liu gan’s legacy is one of innovation and excellence. his work continues to inspire future medical breakthroughs, with ongoing projects poised to revolutionize gastric cancer diagnostics and treatments. his vision for integrating artificial intelligence into oncology holds promise for reshaping the future of cancer care.

Publications

  1. Short- and long-term outcomes following perioperative ERAS management in patients undergoing minimally invasive radical gastrectomy after neoadjuvant chemotherapy: A single-center retrospective propensity score matching study
    Authors: Liu, G., Cao, S., Liu, X., Wang, K., Zhou, Y.
    Year: 2025

 

  1. Deep Learning Radiomics Nomogram Based on Enhanced CT to Predict the Response of Metastatic Lymph Nodes to Neoadjuvant Chemotherapy in Locally Advanced Gastric Cancer
    Authors: Zhong, H., Wang, T., Hou, M., Liu, Z., Zhou, Y.
    Year: 2024

 

  1. Comparison of short- and long-term outcomes between laparoscopic and open gastrectomy for locally advanced gastric cancer following neoadjuvant chemotherapy: a propensity score matching analysis
    Authors: Zhong, H., Liu, X., Tian, Y., Wang, Q., Zhou, Y.
    Year: 2023

 

  1. Intraoperative performance and outcomes of robotic and laparoscopic total gastrectomy for gastric cancer: A high-volume center retrospective propensity score matching study
    Authors: Jia, Z., Cao, S., Meng, C., Wang, Q., Zhou, Y.
    Year: 2023

 

  1. Effect of perioperative probiotic supplements on postoperative short-term outcomes in gastric cancer patients receiving neoadjuvant chemotherapy: A double-blind, randomized controlled trial
    Authors: Liu, G., Cao, S., Liu, X., Zhong, H., Zhou, Y.
    Year: 2022

 

  1. Impact of drinking Chinese green tea on postoperative short outcomes for gastric cancer: a randomized controlled trial
    Authors: Liu, D., Jing, X., Cao, S., Liu, G., Zhou, Y.
    Year: 2021

 

  1. Overexpression of tumour necrosis factor-α induced protein 8 is associated with prognosis in colon cancer
    Authors: Zhang, X., Li, Z., Sun, Y., Liu, X., Zhou, Y.
    Year: 2021

 

  1. Short- and long-term outcomes associated with enhanced recovery after surgery protocol vs conventional management in patients undergoing laparoscopic gastrectomy
    Authors: Tian, Y.-L., Cao, S.-G., Liu, X.-D., Wang, D.-S., Zhou, Y.-B.
    Year: 2020

Conclusion

liu gan’s legacy reflects a profound commitment to enhancing cancer care through research and innovation. his integration of cutting-edge technologies like artificial intelligence into clinical oncology paves the way for future breakthroughs. by inspiring the next generation of medical professionals and driving impactful healthcare solutions, liu’s work ensures lasting progress in the fight against gastric cancer.